The biotechnology space is one of the most exciting and innovative corners of the broader healthcare sector. Some exchange traded funds (ETFs) reflect that innovation including a new fund Global X. The Global X Genomics & Biotechnology ETF (NASDAQ: GNOM) debuted Tuesday.
GNOM tracks the Solactive Genomics Index. The new ETF “seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology,” according to New York-based Global X.
Genomics is widely viewed as a vital area of health sciences and one that has the potential to help people live longer, healthier lives.
“Ultimately, it is believed that a greater understanding of our genetics will empower doctors to conduct more complex medical diagnostics and offer personalized treatments based on an individual’s unique genetic sequence,” according to Global X research. “Such advancements would represent a monumental leap in health care, enabling people to live longer, healthier lives.”
Inside GNOM ETF
About 98% of GNOM’s 40 holdings are classified as biotechnology or life sciences companies. GNOM’s thematic exposure could benefit investors as researchers and scientists tap genomics as a way of treating numerous diseases.
“For many diseases, advances in genomics could offer the first genuine opportunity to cure illnesses previously deemed fatal or without recourse,” said Global X. “Scientists have identified more than 50,000 genetic diseases caused by a single gene mutation in humans, known as Mendelian diseases, which are likely to be the first treated through genomics.”
Adding to the long-term case for GNOM is the fact that gene therapy testing is still in its nascent stages. In the U.S., the Food & Drug Administration (FDA) approved such testing just two years ago. Today, human clinical trials are being held around the world with the hopes of using genomics to find improved treatments and cures for numerous diseases.
“While a truly comprehensive understanding of genetic variation in humans is still far away, the vast scope of genomics highlights the seemingly unparalleled opportunity to develop new treatments for any number of diseases; such potential suggests that genomics’ total addressable market (TAM) could continue to grow rapidly, and for a long time, as each new use case is identified,” according to Global X.
For more information on the biotech segment, visit our biotechnology category.
newETFs.io respects the hard work of others and gives all credit to the remarkable folks at ETFTrends.com. This excerpt/article was pulled from their RSS feed; click here to view the original. Please note that on occasion, the RSS feed will not have the author. When this happens this site defaults the author to "News". Make no mistake, this excerpt/article was not created by newETFs.io, it was simply shared with you.